Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention

T. Šrámková, T. Vaňásek, M. Šrámek, P. Janský, K. Benešová, A. Olšerová, S. Kmetonyová, J. Paulasová-Schwabová, M. Klíma, L. Michal, D. Kala, J. Otáhal, L. Mikšík, A. Tomek

. 2025 ; 104 (21) : e42011. [pub] 20250523

Language English Country United States

Document type Journal Article, Observational Study

Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015674
003      
CZ-PrNML
005      
20250731091149.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MD.0000000000042011 $2 doi
035    __
$a (PubMed)40419880
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šrámková, Tereza $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000719691832
245    10
$a Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention / $c T. Šrámková, T. Vaňásek, M. Šrámek, P. Janský, K. Benešová, A. Olšerová, S. Kmetonyová, J. Paulasová-Schwabová, M. Klíma, L. Michal, D. Kala, J. Otáhal, L. Mikšík, A. Tomek
520    9_
$a Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a cerebrální krvácení $x chemicky indukované $x diagnostické zobrazování $x epidemiologie $7 D002543
650    12
$a antikoagulancia $x škodlivé účinky $x terapeutické užití $7 D000925
650    _2
$a lidé středního věku $7 D008875
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    12
$a sekundární prevence $x metody $7 D055502
650    _2
$a dabigatran $x škodlivé účinky $x terapeutické užití $7 D000069604
650    _2
$a incidence $7 D015994
650    _2
$a pyridony $x škodlivé účinky $x terapeutické užití $7 D011728
650    12
$a cévní mozková příhoda $x prevence a kontrola $7 D020521
650    _2
$a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Vaňásek, Tomáš $u Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000242762321
700    1_
$a Šrámek, Martin $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $u Department of Neurology, Military University Hospital Prague, Czech Republic $1 https://orcid.org/0000000255199876 $7 xx0071056
700    1_
$a Janský, Petr $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000331590958
700    1_
$a Benešová, Kateřina $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000793698434
700    1_
$a Olšerová, Anna $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000230571387
700    1_
$a Kmetonyová, Silvia $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000347653378
700    1_
$a Paulasová-Schwabová, Jaroslava $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000284658269
700    1_
$a Klíma, Michal $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $u Department of Neurology, Jihlava Hospital, Czech Republic
700    1_
$a Michal, Lukáš $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000818715385
700    1_
$a Kala, David $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000230101174
700    1_
$a Otáhal, Jakub $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000159445803 $7 xx0105144
700    1_
$a Mikšík, Lukáš $u Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic
700    1_
$a Tomek, Aleš $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00012436 $t Medicine $x 1536-5964 $g Roč. 104, č. 21 (2025), s. e42011
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40419880 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091144 $b ABA008
999    __
$a ok $b bmc $g 2366497 $s 1252799
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 104 $c 21 $d e42011 $e 20250523 $i 1536-5964 $m Medicine $n Medicine (Baltimore) $x MED00012436
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...